Intra-Cellular Therapies (ITCI) Tops Q2 EPS by 3c ; Offers Guidance

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q2 EPS of ($0.16), $0.03 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $161.4 million versus the consensus estimate of $158.1 million.

GUIDANCE:

Intra-Cellular Therapies sees FY2024 revenue of $650-680 million, versus the consensus of $662.2 million.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

You May Also Be Interested In

• Walmart to pay $1.4 billion for Vibe.co acquisition - WSJ
• Bernstein SocGen Group Reiterates Outperform Rating on Hermes International (RMS:FP) (HESAY) after cautious commentary
• Genco Shipping & Trading Limited (GNK) 8400 contracts of August 30 calls trade, share price up 5.5%